R
Redx Pharma PLC
LSE:REDX
Redx Pharma PLC
LSE:REDX
Price:
15 GBX
31.58%
Market Closed
Updated:
May 6, 2024
Section:
Relative Value
The Relative Value of one REDX stock under the Base Case scenario is 10.25 GBX. Compared to the current market price of 15 GBX, Redx Pharma PLC is Overvalued by 32%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
REDX
Relative Value
Base Case
10.25
GBX
Overvaluation 32%
R
Valuation Multiples
Multiples Across Competitors
REDX Competitors Multiples
Redx Pharma PLC Competitors
Redx Pharma PLC Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| UK |
R
|
Redx Pharma PLC
LSE:REDX
|
50.2m GBP | 12 | -1.5 | -1.6 | -1.6 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
716.9B USD | 20 | 116.8 | 57.2 | 65.1 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
3.8T DKK | 16.4 | 45.4 | 33.2 | 36.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
356.2B USD | 4.2 | 9.3 | 11.4 | 14.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
321.2B USD | 5.2 | 139.3 | 33.2 | 52.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
186.8B GBP | 5.1 | 39.4 | 140.7 | 225.7 | |
| CH |
|
Novartis AG
SIX:NOVN
|
180B CHF | 4.3 | 13.4 | 9.8 | 16.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
174.5B CHF | 3 | 15.2 | 8.6 | 10.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
158.8B USD | 2.9 | -513.9 | 12.8 | 20.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
